[CAR-T therapy for malignant lymphoma].

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), is a heterogeneous malignancy.
• Relapsed or refractory (R/R) disease presents a significant challenge with poor prognosis.
• Chimeric antigen receptor T-cell (CAR-T) therapy represents a paradigm shift in managing R/R B-cell lymphomas.

Approach:

• Review of pivotal trials and real-world data for FDA-approved CD19 CAR-T therapies (Yescarta®, Kymriah®, Breyanzi®).
• Analysis of efficacy, including complete response (CR) rates and long-term remission.
• Evaluation of safety profiles, focusing on cytokine release syndrome, neurotoxicity, cytopenias, and hypogammaglobulinemia.

Key Points:

• CD19 CAR-T therapy shows CR rates of 40-60% in R/R DLBCL and R/R FL.
• A notable subset of patients achieve durable, long-term disease remission.
• Manageable toxicities like cytokine release syndrome and neurotoxicity are generally reversible.

Conclusions:

• CAR-T therapy is transforming the treatment landscape for R/R DLBCL and FL.
• Real-world data supports the efficacy observed in clinical trials.
• Understanding efficacy and toxicity is crucial for patient management and future therapeutic development.